Shandong Pharmaceutical Glass Co Ltd
SSE:600529
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
CN |
S
|
Shandong Pharmaceutical Glass Co Ltd
SSE:600529
|
18.8B CNY | 229.1 | |
CH |
Alcon AG
SIX:ALC
|
39.4B CHF | 135.1 | ||
JP |
Hoya Corp
TSE:7741
|
6.3T JPY | 39.6 | ||
DK |
Coloplast A/S
CSE:COLO B
|
187.7B DKK | 68.3 | ||
US |
Align Technology Inc
NASDAQ:ALGN
|
20.9B USD | 34.4 | ||
US |
Cooper Companies Inc
NYSE:COO
|
19.1B USD | 81.7 | ||
KR |
H
|
HLB Inc
KOSDAQ:028300
|
12.3T KRW | -101.4 | |
CN |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
60.5B CNY | 53.5 | ||
UK |
ConvaTec Group PLC
LSE:CTEC
|
5.4B GBP | 39.8 | ||
US |
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
5.8B USD | 26.5 | ||
US |
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.5B USD | 26.7 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.